1 drenal pheochromocytoma, and 9 patients with extraadrenal abdominal paraganglioma (1 nonmetastatic, 8

2 F-DOPA PET for adrenal pheochromocytomas and extraadrenal abdominal paragangliomas by increasing the

3 adrenal, including 2 malignant tumors, and 3 extraadrenal, including 1 malignant tumor).

4 opulations of adrenal (pheochromocytoma) and extraadrenal (paraganglioma) tumors, sensitivities were

5 )F-DOPA PET of adrenal pheochromocytomas and extraadrenal paragangliomas is unknown.

6 nt had a hepatic angioma, one patient had an extraadrenal pheochromocytoma, one patient had an absces

7                    Patients with adrenal and extraadrenal pheochromocytomas also had similar rates of

8          The data suggest that patients with extraadrenal pheochromocytomas have the same risk of mal

9 udies report a higher rate of malignancy for extraadrenal pheochromocytomas than for adrenal pheochro

10                                        Of 26 extraadrenal pheochromocytomas, 14 were initially consid

11 tatistically significant between adrenal and extraadrenal pheochromocytomas.

12 nts had progression of metastatic disease at extraadrenal sites.

13  primary adrenal lymphoma and no evidence of extraadrenal spread who was evaluated from presentation

14 bed produces cortisol at rates approximating extraadrenal tissues by converting cortisone to cortisol